Comment faire évoluer le paradigme du développement clinique et son découpage en phases I, II, III-Reference-Cited by-同舟云学术

Comment faire évoluer le paradigme du développement clinique et son découpage en phases I, II, III

Published:2011-07 Issue:4 Volume:66 Page:327-330
ISSN:0040-5957
Container-title:Therapies
language:fr
Short-container-title:Therapies

Author:

Bamberger Marion,Moore Nicholas,Lechat Philippe,Azizi Michel,Blin Patrick,Bouhassira Myriam,Cellier Dominic,Demarez Jean-Paul,Duval Xavier,Gueyffier François,Le Jeunne Claire,Libersa Christian,Mahlberg-Gaudin Florence,Maison Patrick,Marquet Pierre,Molimard Mathieu,Moser Aurélie,Pavlovic Mira,Piedbois Pascal,Regnier Odile,Reynier Jean-Charles,Rey-Quinio Catherine,Rossignol Patrick,Spriet Alain,Vignal Franck

Publisher

Elsevier BV

Subject

Pharmacology (medical)

Reference17 articles.

1. An adaptive seamless phase II/III design for oncology trials with subpopulation selection using correlated survival endpointsdagger;Jenkins;Pharm Stat,2010

2. A Bayesian adaptive design with biomarkers for targeted therapies;Eickhoff;Clin Trials,2010

3. Perspectives on the use of adaptive designs in clinical trials. Part II. Panel discussion;Benda;J Biopharm Stat,2010

4. Comments on the draft guidance on "adaptive design clinical trials for drugs and biologics" of the U.S. Food and Drug Administration;Brannath;J Biopharm Stat,2010

5. Introduction to discussion papers on draft FDA guidance on adaptive designs;Chang;J Biopharm Stat,2010

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Observational Studies Requested by European Health Authorities: Governmental Interference or an Enhancement of Everyday Urological Practice? The Hexvix® Observational Patients Evaluation Study as an Example of What to Expect;Urologia Internationalis;2017

2. In silico tools used for compound selection during target-based drug discovery and development;Expert Opinion on Drug Discovery;2015-05-08